Drug Development

Weight Loss Cancer Drugs Repurposing Drugs Biomarkers Pipeline Programs Precision Medicine Rare Diseases Regulatory Approvals Hormonal Research Phase 3 Trials Efficacy Studies Phase I Trials Preclinical Testing Male Contraceptive Trials Neurological Disorders Oncology Pilot Studies

5 ARTICLES

last wk.

SYNT-101 Shows Promise in Early Human Trials as a Non-Invasive Obesity Treatment

The once-daily oral pill mimics gastric bypass surgery by temporarily coating the duodenum, demonstrating safety and metabolic effects in a nine-participant pilot study.

5 ARTICLES

4w ago

GSK Acquires US Biotech IDRx in $1.15 Billion Deal to Advance Rare Cancer Treatment

4 ARTICLES

8mo ago

Antidepressant Vortioxetine Shows Potential in Treating Aggressive Brain Tumors

6 ARTICLES

last yr.

Roche's Experimental Obesity Drug CT-388 Shows Significant Weight Loss in Early Trials

Drug Development

SYNT-101 Shows Promise in Early Human Trials as a Non-Invasive Obesity Treatment

Adam Male Contraceptive Implant Shows Two-Year Efficacy in Phase 1 Trials

Sanofi Secures $1.9 Billion Deal for Dren Bio’s Innovative Autoimmune Therapy

AstraZeneca Acquires Belgian Biotech EsoBiotec in $1 Billion Deal

GSK Acquires US Biotech IDRx in $1.15 Billion Deal to Advance Rare Cancer Treatment

Antidepressant Vortioxetine Shows Potential in Treating Aggressive Brain Tumors

Roche's Experimental Obesity Drug CT-388 Shows Significant Weight Loss in Early Trials